CBSC secures Health Canada license for CardioHolter AT with $375K order from Your Heart Protector Corp, expanding cardiac monitoring in Canada.

Sep 25

Cardiac Biotech

Cardiac Biotech

Cardiac Biotech Solutions, Inc. Secures Health Canada License for MyCardia AT Device, Now Branded as CardioHolter AT

CBSC secures Health Canada license for CardioHolter AT, lands $375K order with Your Heart Protector Corp, expanding into Canadian market.
CBSC announces $375,000 Noventis Medical purchase order and new recurring revenue program for MyCardia AT cardiac monitoring devices.

Sep 11

Cardiac Biotech

Cardiac Biotech

CBSC Announces $375,000 Purchase Order and Launch of Recurring Revenue Program with Noventis Medical

CBSC secures $375K purchase order with Noventis Medical and launches recurring revenue program for MyCardia AT devices.
Cardiac Biotech Solutions signs exclusive $600K Noventis Medical distribution agreement for Latin America.

Sep 04

Cardiac Biotech

Cardiac Biotech

Cardiac Biotech Solutions, Inc. (CBSC) Signs Exclusive 5-Year Distribution Agreement with Noventis Medical Covering Costa Rica, Panama, Colombia, and Argentina

Cardiac Biotech Solutions, Inc. signs $600K exclusive distribution deal with Noventis Medical, expanding cardiac monitoring reach into Latin America.

May 08

Cardiac Biotech

Cardiac Biotech

CB Scientific, Inc. (CBSC) Announces Corporate Name Change to Cardiac Biotech Solutions, Inc.

CB Scientific, Inc. is now Cardiac Biotech Solutions, Inc., reflecting our mission to deliver advanced, cloud-connected cardiac monitoring technologies across global healthcare markets.

Feb 25

Cardiac Biotech

Cardiac Biotech

Officially Launches Next-Generation MyCardia AT Cardiac Monitor

CB Scientific, Inc. (CBSC) has officially launched its next-generation MyCardia AT cardiac event monitor in collaboration with Datrix, LLC. Designed for enhanced remote cardiac monitoring, the FDA-cleared device offers a lightweight, easy-to-use design with seamless integration into the MyCardia app ecosystem. The MyCardia AT monitor enables early detection of cardiac arrhythmias, helping physicians diagnose transient heart conditions more effectively. The device is set to roll out across SE Asia, Hong Kong, Macau, and pending regulatory approvals, Canada and China.

Oct 03

Cardiac Biotech

Cardiac Biotech

Trip Thomas Appointed as Chief Financial Officer

William "Trip" Thomas appointed Chief Financial Officer, succeeding Brooke Turk. Trip Thomas is a licensed CPA with extensive experience in financial reporting and regulatory compliance.

Aug 20

Cardiac Biotech

Cardiac Biotech

CB Scientific, Inc. Announces Voluntary Delisting from OTCQB Venture Market

CB Scientific, Inc. announces its voluntary delisting from the OTCQB Venture Market to preserve capital for future business growth. The company's common shares will continue trading on the OTC Pink Open Market.

Dec 14

Cardiac Biotech

Cardiac Biotech

Entered Beta-testing Phase for Updated Proprietary myCam Cardiac Event Monitor

Updates to provide device improvements while maintaining the innovative core-functionality of CBSC's state of the art cardiac event monitor.

Dec 07

Cardiac Biotech

Cardiac Biotech

Executed Manufacturing Letter of Intent with Shenzhen Pump Medical System Co., Ltd.

Partnership to provide high-volume manufacturing capability and facilitate obtaining requisite government approvals.

Nov 30

Cardiac Biotech

Cardiac Biotech

Announcing Intent to Convene a Special Meeting of the Stockholders

Agenda to include matters necessary to better position the company for anticipated growth and development.
  • 1
  • 2

How can we help you?

Contact Us

© 2020-2025. Cardiac Biotech Solutions, Inc. - All rights reserved. | Designer

Get our news in your inbox!

Join our newsletter and we will send our news directly to you.